Supplementary Figure S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Figure S4. (A) Time to sustained myeloid recovery stratified by CH-R alone, with medians and hazard ratio (HR) with 95% confidence interval (CI) shown. (B) Time to sustained myeloid recovery, stratified by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin (ferr.) and by CH-R, with medians and adjusted hazard ratios (aHR) with 95% CI after multivariable model also including age, prior lines of therapy, and high-risk cytogenetic abnormalities. CH-R is clonal hematopoiesis restricted only to mutations in DNMT3A, TET2, ASXL1, or PPM1D.